Joseph D. Keegan

Dr. Keegan has more than 30 years of experience in life science businesses. Most recently as CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M. During his 9 year tenure as CEO at Molecular Devices Corporation, he grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M. He currently serves on the Boards of Directors of Arrayjet Ltd, Bio-Techne (NASDAQ:TECH), Halo Labs as Executive Chairman, Fluidic Analytics Ltd as Chairman, Interpace Biosciences (NASDAQ:IDXG) and Nuclera Nucleics Ltd. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.